At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 893 enrolled
Drug / intervention
Tazarotene (Fabior™) +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Double-Blind, Randomized, Parallel-Group, Vehicle-Controlled Study to Evaluate the Safety and Therapeutic Equivalence of a Generic Tazarotene Foam 0.1%(Actavis) and the Reference Listed Fabior™(Tazarotene Foam, 0.1%) (Stiefel Laboratories, Inc.) in Treatment of Subjects With Acne Vulgaris
In Brief
A Phase 3 clinical trial evaluating Tazarotene (Fabior™), Tazarotene (Actavis), and 1 other intervention for Acne Vulgaris. Completed, enrolled 893 participants across 15 sites in 2 countries.
Detailed Summary
The purpose of this study is to compare the safety and therapeutic equivalence of a generic tazarotene foam 0.1% and the reference listed Fabior™ (tazarotene foam, 0.1%) in the treatment of acne vulgaris.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcne Vulgaris
CountriesBelize, United States
Collaborators--
Timeline
Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartJun 2014
Primary CompletionSep 2014
First PostedOct 2014
TodayJul 2026
First PostedOct 17, 2014
Enrollment StartJun 1, 2014
Primary CompletionSep 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 11.7 years ago
Interventions
Tazarotene (Fabior™)drug
Tazarotene (Actavis)drug
Vehicle foamdrug